Eric Joseph Analyst PerformanceDirector, Senior Analyst at CitigroupEric Joseph is a stock analyst at Citigroup focused in the medical sector, covering 22 publicly traded companies. Over the past year, Eric Joseph has issued 14 stock ratings, including strong buy, buy, and hold recommendations. While full access to Eric Joseph's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Eric Joseph's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings34 Last 5 YearsBuy Recommendations70.59% 24 Buy RatingsCompanies Covered22 Unique Companies Ratings Distribution34RatingsDistribution of strong buy, buy, hold, and sell ratings by Eric Joseph.RatingPercentageCount Strong Buy14.7%5 ratings Buy55.9%19 ratings Hold23.5%8 ratings Sell5.9%2 ratingsOut of 34 total stock ratings issued by Eric Joseph at Citigroup, the majority (55.9%) have been Buy recommendations, followed by 23.5% Hold, 14.7% Strong Buy, and 5.9% Sell.Best & Worst CallsBest Call000.0%PTCTMay 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%AVIROct 2021Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ22 companiesEric Joseph, an analyst at Citigroup, currently covers 22 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical21 companies95.5%Manufacturing1 company4.5%Eric Joseph of Citigroup specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE15 companies68.2%MED - DRUGS3 companies13.6%MED - GENERIC DRG1 company4.5%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES1 company4.5%MED INSTRUMENTS1 company4.5%MED PRODUCTS1 company4.5% Eric Joseph's Ratings History at Citigroup Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsALNYAlnylam Pharmaceuticals5/19/2026Initiated Coverage$286.27$380.00Buy$0.0000.00% ROIBMRNBioMarin Pharmaceutical5/19/2026Initiated Coverage$49.67$75.00Buy$0.0000.00% ROIBBIOBridgeBio Pharma5/19/2026Initiated Coverage$65.32$82.00Neutral$0.0000.00% ROIASNDAscendis Pharma A/S5/18/2026Initiated Coverage$237.64$355.00Buy$0.0000.00% ROIIONSIonis Pharmaceuticals5/18/2026Initiated Coverage$72.52$115.00Buy$0.0000.00% ROICYTKCytokinetics5/18/2026Initiated Coverage$75.18$99.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals5/18/2026Upgrade$294.30Strong-Buy$0.0000.00% ROIASNDAscendis Pharma A/S5/18/2026Upgrade$237.96Strong-Buy$0.0000.00% ROIBMRNBioMarin Pharmaceutical5/18/2026Upgrade$49.84Strong-Buy$0.0000.00% ROICYTKCytokinetics5/18/2026Upgrade$76.45Strong-Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. IONSIonis Pharmaceuticals5/18/2026Upgrade$73.84Strong-Buy$0.0000.00% ROIRXRXRecursion Pharmaceuticals12/17/2025Upgrade$4.20$11.00Overweight$0.0000.00% ROITGTXTG Therapeutics11/3/2025Boost Price Target$32.85$49.00Overweight$0.0000.00% ROIBEAMBeam Therapeutics10/9/2025Lower Price Target$25.53$46.00Overweight$0.0000.00% ROIKYMRKymera Therapeutics6/3/2025Boost Price Target$43.13$64.00Overweight$00.0000.00% ROIPRMEPrime Medicine5/20/2025Reiterated Rating$1.34Neutral$0.0000.00% ROIRCKTRocket Pharmaceuticals5/9/2025Lower Price Target$6.97$44.00Overweight$0.0000.00% ROINVAXNovavax5/9/2025Lower Price Target$5.99$7.00Underweight$00.0000.00% ROIPTCTPTC Therapeutics5/7/2025Lower Price Target$36.19$67.00Overweight$00.0000.00% ROIOPKOPKO Health4/25/2025Initiated Coverage$1.46Neutral$0.0000.00% ROIPTCTPTC Therapeutics3/31/2025Lower Price Target$47.86$75.00Overweight$00.0000.00% ROIPTCTPTC Therapeutics3/14/2025Boost Price Target$55.17$78.00Overweight$00.0000.00% ROIPTCTPTC Therapeutics2/28/2025Lower Price Target$54.76$72.00Overweight$00.0000.00% ROIPLRXPliant Therapeutics2/10/2025Downgrade$7.79Neutral$0.0000.00% ROINRIXNurix Therapeutics1/29/2025Lower Price Target$19.56$30.00Overweight$00.0000.00% ROIIGMSIGM Biosciences1/13/2025Upgrade$1.87Neutral$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James Financial Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
